New drug shows promise for tough hodgkin lymphoma cases
NCT ID NCT04318080
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This Phase 2 trial tested the drug tislelizumab in 46 people with classical Hodgkin lymphoma that had come back or was not responding to treatment. The main goal was to see how many participants had their tumors shrink or disappear. Participants received the drug every 3 weeks until their disease worsened or side effects became too severe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tislelizumab (a drug that helps the immune system attack cancer cells)
What this could lead to
If successful, this could provide a new treatment option for people with Hodgkin lymphoma that has come back or not responded to other therapies.
What could go wrong
This is a small, early-phase trial (Phase 2) with only 46 participants. The drug may not work for everyone, and side effects could be severe. More research is needed before it becomes widely available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLASSICAL HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, 48201-2013, United States
-
Huntsman Cancer Institute
Salt Lake City, Utah, 84112-5550, United States
-
Monash Health
Clayton, Victoria, VIC 3168, Australia
-
University of Tennessee Medical Center
Knoxville, Tennessee, 37920-1511, United States